<DOC>
	<DOCNO>NCT01858766</DOCNO>
	<brief_summary>The primary objective study evaluate antiviral efficacy , safety , tolerability sofosbuvir ( SOF ) + velpatasvir ( VEL ; GS-5816 ) without ribavirin ( RBV ) treatment-naive adult chronic genotype ( GT ) 1 , 2 , 3 , 4 , 5 , 6 hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Safety Efficacy Sofosbuvir + Velpatasvir With Without Ribavirin Treatment-Naive Adults With Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Chronic HCV infection Body mass index ( BMI ) ≥ 18 kg/m^2 HCV RNA ≥ 10000 IU/mL screen Use highly effective contraception method female childbearing potential sexually active male Must cirrhosis Current prior history clinically significant illness HCV Screening ECG clinically significant abnormality Prior exposure HCV specific direct act antiviral agent Prior treatment HCV interferon ribavirin Pregnant nursing female male pregnant female partner Chronic liver disease nonHCV etiology Hepatitis B Active drug abuse Use prohibit concomitant medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>HCV Genotype 1</keyword>
	<keyword>HCV Genotype 2</keyword>
	<keyword>HCV Genotype 3</keyword>
	<keyword>HCV Genotype 4</keyword>
	<keyword>HCV Genotype 5</keyword>
	<keyword>HCV Genotype 6</keyword>
	<keyword>treatment naive</keyword>
</DOC>